Physician profile
Robert A Lyons
NPI 1699712034
$2,774.73
in general payments reported to CMS, 2019-2025
28 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2020: $160 · 2022: $480 · 2023: $695 · 2024: $328 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $449.54 | 2019-2025 | |
| Amgen INC. | $398.25 | 2019-2024 | Repatha, Evenity, Prolia |
| Abbvie INC. | $309.83 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.04 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $214.39 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $178.45 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $147.84 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $106.52 | 2020-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $101.45 | 2019-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $96.86 | 2019-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $79.64 | 2019-2022 | |
| Antares Pharma, INC. | $77.39 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Teva Pharmaceuticals USA, INC. | $67.63 | 2019-2023 | Ajovy |
| Janssen Pharmaceuticals, INC | $50.18 | 2023-2024 | Spravato, Xarelto |
| Exact Sciences Corporation | $37.33 | 2023 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.15 | 2019-2024 | |
| Halozyme INC | $23.72 | 2023 | |
| Glaxosmithkline, LLC. | $22.67 | 2025 | Trelegy Ellipta |
| Allergan, INC. | $22.19 | 2019 | |
| Stryker Corporation | $22.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.60 | 2023 | |
| Lucid Diagnostics INC. | $17.01 | 2022 | |
| Genentech USA, INC. | $16.17 | 2019 | |
| Boston Scientific Corporation | $15.90 | 2025 | General - Pain Management |
| Organon LLC | $15.02 | 2022 | |
| Linus Health, INC. | $14.23 | 2024 | Core Cognitive Evaluation |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.41 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.